Neurocrine Biosciences (NBIX) Cash from Investing Activities Growth (1y) (2011 - 2026)
Powered by 
Analysis
Neurocrine Biosciences (NBIX) Cash from Investing Activities Growth (1y) (2011 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 643.26 Bn | 622.50 Bn | 17.26 Bn | 93.92% |
| 2 | AbbVie | 443.31 Bn | 436.74 Bn | 12.70 Bn | -1.35% |
| 3 | Merck | 364.74 Bn | 357.60 Bn | 12.21 Bn | -627.53% |
| 4 | Novartis Ag | 266.46 Bn | 258.77 Bn | 11.24 Bn | -38.43% |
| 5 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | -46.70% |
| 6 | Sanofi | 52.33 Bn | 44.95 Bn | 10.79 Bn | -103.94% |
| 7 | Revolution Medicines | 43.79 Bn | 43.79 Bn | - | - |
| 8 | Incyte | 25.23 Bn | 20.69 Bn | 1.57 Bn | -174.44% |
| 9 | United Therapeutics | 21.67 Bn | 19.01 Bn | 683.80 Mn | 129.18% |
| 10 | Neurocrine Biosciences | 15.65 Bn | 15.26 Bn | 935.80 Mn | -366.90% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -366.90% |
| Mar 31, 2026 | -3,664.79% |
| Dec 31, 2025 | 22.55% |
| Sep 30, 2025 | -896.36% |
| Jun 30, 2025 | -2.84% |
| Mar 31, 2025 | 125.82% |
| Dec 31, 2024 | 66.15% |
| Sep 30, 2024 | 125.39% |
| Jun 30, 2024 | 77.60% |
| Mar 31, 2024 | -30.64% |
| Dec 31, 2023 | -74.57% |
| Sep 30, 2023 | -58.73% |
| Jun 30, 2023 | -500.96% |
| Mar 31, 2023 | -33.23% |
| Dec 31, 2022 | -587.76% |
| Sep 30, 2022 | 51.43% |
| Jun 30, 2022 | 134.58% |
| Mar 31, 2022 | -150.08% |
| Dec 31, 2021 | 116.05% |
| Sep 30, 2021 | -600.79% |